Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new?
The article is devoted to the role of respiratory fluoroquinolones in the treatment of community-acquired pneumonia. Respiratory fluoroquinolones are key in the treatment of the disease as they affect virtually all pathogens of community-acquired pneumonia, and have attractive pharmacokinetic and ph...
Main Author: | A. I. Sinopalnikov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2014-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/760 |
Similar Items
-
Moxifloxacin: safety profile
by: A. I. Sinopalnikov
Published: (2013-12-01) -
Effectiveness of antimicrobial therapy for community-acquired pneumonia in real clinical practice
by: O. M. Uryasev, et al.
Published: (2022-01-01) -
Community-acquired pneumonia against a background of chronic heart failure: diagnosis and treatment
by: A. A. Bobylev, et al.
Published: (2014-12-01) -
Respiratory fluoroquinolones in outpatient clinical practice
by: R. S. Kozlov, et al.
Published: (2015-12-01) -
Ofloxacin induced hallucinations in a 6 years old child: A case report
by: Prashant Chaudhari, et al.
Published: (2019-01-01)